Tas 120

Manufactured by Cayman Chemical

Sourced in United States

The TAS-120 is a laboratory instrument used for the analysis and detection of chemical compounds. It is designed to provide precise and accurate measurements of various analytes. The core function of the TAS-120 is to perform high-sensitivity analysis and quantification of target molecules. Detailed specifications and technical details are available upon request.

Automatically generated - may contain errors

Lab products found in correlation

Ponatinib, by Cayman Chemical (2 mentions) Dovitinib, by Cayman Chemical (2 mentions) Azd 4547, by Cayman Chemical (2 mentions) Erlotinib, by ChemScene (1 mentions) Fisogatinib, by Selleck Chemicals (1 mentions) Cetuximab, by Merck Group (1 mentions) Bgj398, by Cayman Chemical (1 mentions) Jnj 42756493, by Cayman Chemical (1 mentions) Celltiter 96 aqueous non radioactive cell proliferation assay, by Promega (1 mentions)

3 protocols using tas 120

Evaluating FGFR and EGFR Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Erdafitinib (JNJ42756493, pan-FGFR1–4 inhibitor; Active Biochem, Kowloon, Hong Kong), AZD4547 (FGFR1–3 inhibitor; Active Biochem), infigratinib (BGJ398, FGFR1–3 inhibitor; AdooQ, Irvine, CA, USA), fisogatinib (BLU554, FGFR4-selective inhibitor; Selleck Chemicals, Houston, TX), rogaratinib (BAY1163877, FGFR1–3 inhibitor; MedChemo Express, Monmouth Junction, NJ), LY2874455 (Chem Scene, pan-FGFR1–4 inhibitor; Monmouth Junction, NJ), TAS-120 (pan-FGFR1–4 inhibitor; Cayman Chemical Company, Ann Arbor, MI), and erlotinib (EGFR inhibitor; Chem Scene) were dissolved and diluted in DMSO. Cetuximab (Erbitux, anti-EGFR antibody, Merck, Kenilworth, NJ) was diluted in PBS.

Yamamoto T., Miyoshi H., Kakizaki F., Maekawa H., Yamaura T., Morimoto T., Katayama T., Kawada K., Sakai Y, & Taketo M.M. (2020). Chemosensitivity of Patient-Derived Cancer Stem Cells Identifies Colorectal Cancer Patients with Potential Benefit from FGFR Inhibitor Therapy. Cancers, 12(8), 2010.

+ Open protocol

+ Expand

Evaluating FGFR Inhibitor Potency

Check if the same lab product or an alternative is used in the 5 most similar protocols

NIH3T3 cells were plated at 10,000 cells per well in 96-well plates in sextuplets. Cells were treated for 72 h with various selective and non-selective FGFR inhibitors ranging from0.01 to 5000 nM followed by quantification of viable cells using an MTS/PMS colorimetric assay. FGFR inhibitors tested include BGJ398, JNJ-42756493, AZD-4547, Ponatinib, Dovitinib, and TAS-120 (Cayman Chemical). The half maximal inhibitory concentration (IC₅₀) of each FGFR inhibitor was calculated with GraphPad Prism using a four-parameter dose-response curve from four independent experiments.

Krook M.A., Barker H., Chen H.Z., Reeser J.W., Wing M.R., Martin D., Smith A.M., Dao T., Bonneville R., Samorodnitsky E., Miya J., Freud A.G., Monk J.P., Clinton S.K, & Roychowdhury S. (2019). Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. Prostate cancer and prostatic diseases, 22(4), 624-632.

+ Open protocol

+ Expand

FGFR Inhibitor Cytotoxicity Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

NIH3T3 and 293T cells were plated at 10,000 cells per well and MMNK-1 were plated at 5,000 cells per well in a 96-well plate and allowed to adhere for 24 hours. Cells were dosed with varying concentrations (0.01 to 5000 nM) of FGFR inhibitors and allowed to incubate for 72 hours. FGFR inhibitors tested included infigratinib, AZD4547 (22 (link)), erdafitinib, TAS120 (23 (link)), dovitinib, and ponatinib (Cayman Chemical). Quantification of viability was carried out with the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega) per manufacturer’s protocol. The half maximal inhibitory concentration (IC₅₀) was calculated using GraphPad Prism. Four independent replicate experiments were conducted.

Krook M.A., Lenyo A., Wilberding M., Barker H., Dantuono M., Bailey K.M., Chen H.Z., Reeser J.W., Wing M.R., Miya J., Samorodnitsky E., Smith A.M., Dao T., Martin D.M., Ciombor K.K., Hays J., Freud A.G, & Roychowdhury S. (2020). Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Molecular cancer therapeutics, 19(3), 847-857.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!